- Home
- LSF vs RLYB Comparison
LSF vs RLYB Comparison
Compare LSF & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | RLYB |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 24.1M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LSF | RLYB |
|---|---|---|
| Price | $2.02 | $0.78 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 118.8K | ★ 205.9K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,146,862.00 | $674,000.00 |
| Revenue This Year | $18.05 | $17.61 |
| Revenue Next Year | $17.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.73 | 12.71 |
| 52 Week Low | $1.99 | $0.22 |
| 52 Week High | $8.96 | $1.08 |
Technical Indicators
Market Signals| Indicator | LSF | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 28.75 | 63.06 |
| Support Level | $1.99 | $0.71 |
| Resistance Level | $2.25 | $0.80 |
| Average True Range (ATR) | 0.19 | 0.05 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 3.80 | 82.82 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.